Articles related to BREAST SURGERY

The majority of the decrease in the risk of local recurrence was seen in the first decade, according to the researchers’ observations of a differential effect over time. With or without irradiation, the risk of recurrence is not significantly different in the second decade. However, others pointed out that the goal of radiotherapy is not to increase overall survival but rather to lower the risk of local recurrence, which is a crucial aspect of breast-conserving therapy.

This six-chapter video series covers patient selection for neoadjuvant systemic treatment, adjuvant systemic treatment, neoadjuvant systemic treatment, post-neoadjuvant adjuvant treatment, survivorship and surveillance, and future directions.

Joyce A. O’Shaughnessy, MD provides updates on several key presentations from SABCS, touching on SERD therapy, ribociclib combinations, the datopotamab deruxtecan antibody-drug conjugate targeting overexpression of the calcium signal transducer TROP2, trastuzumab deruxtecan, and more. The MONALEESA phase 3 trial is looking at letrozole + ribociclib vs letrozole + placebo in postmenopausal women with ER+ HER2- advanced breast cancer. The trial arm outperformed the control arm with a median OS of 63.9 months vs 51.4 months respectively at a median follow up of just over 6.5 years. That median OS is the longest reported for any phase 3 trial in advanced breast cancer.